Independent Franchise Partners Adds $26M in Bristol-Myers Squibb Company ($BMY)
Key Points
- Independent Franchise Partners changed its Bristol-Myers Squibb Company ($BMY) stake by 2.15% last quarter, boosting to 21,275,474 shares worth $1.23 billion.
- Wall Street's consensus rating on $BMY is Buy and an average price target of $66.21.
- $BMY last traded around $57.62.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Independent Franchise Partners increased its position in Bristol-Myers Squibb Company ($BMY) by 2.15% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,275,474 shares of Bristol-Myers Squibb Company after buying 447,326 shares during the quarter. Independent Franchise Partners's holdings in Bristol-Myers Squibb Company were worth $1.23 billion as of its most recent filing.
Bristol-Myers Squibb Company Stock Down 13.5%
Shares of Bristol-Myers Squibb Company ($BMY) traded around $57.62 on Saturday, down 13.5% for the day.
Bristol-Myers Squibb Company Earnings
Bristol-Myers Squibb Company Dividend
Analysts Set New Price Targets
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Get Bristol-Myers Squibb Company alerts
New 13F filings, insider trades, and analyst moves on $BMY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.